Magnetic particle tagged reagents and techniques

ABSTRACT

Methods for separating, cells, particles, or other molecules of interest (MOI) from unwanted materials not of interest (MNOI). by forced movement of MOI into certain zones having properties which deter the entry of unwanted materials. MOI are tagged with magnetic particles and moved with a magnetic field through a fluid, or zones, of higher specific gravity that prevents, unwanted less dense materials from entering. Buoyant or other forces are used to remove any unbound material from the complexes with ASG before reading. Readable labels include the magnetic particle tagged complex itself, and other labels such as enzymes, chemiluminescent materials, radioactive isotopes, chromogenic and fluorogenic substrates and other labels may be used. The invention applies to many assays, diagnostic tests, separative procedures and chemical syntheses.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.11/715,411 filed Mar. 8, 2007 which in turn is a continuation-in-part ofU.S. application Ser. No. 11/518,189 filed Sep. 11, 2006, which claimsthe benefit of U.S. Provisional Application 60/716,591, filed Sep. 13,2005.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT (NotApplicable) REFERENCE TO A SEQUENCE LISTING, A TABLE, OR A COMPUTERPROGRAM LISTING APPENDIX SUBMITTED ON COMPACT DISC (SEE 37 CFR1.52(e)(5)) (Not Applicable) FIELD OF THE INVENTION

This invention relates to a method for separating cells, particles, andmolecules or analytes, unreacted reagents, and other materials ofinterest from associated or contaminating material or unwanted materialsuch as proteins, for use in many assays, diagnostic procedures, andpreparative processes.

More particularly, it relates to performing the above procedures by anovel method whereby cells, particles, molecules, analytes or othermaterials of interest are separated from a liquid mixture or surfacecontaining contaminating or interfering materials by a novel processutilizing buoyant forces with reactive magnetic particles and liquids ofselected specific gravity and magnetic forces.

The invention also relates to cell separations and microscopy,immunoassays, chemical synthesis, molecular separations and particularlyto blood bank diagnostics as well as many other scientific proceduresand industrial manufacturing and quality control processes, whereinmagnetic particles and magnetic forces are used to effect the separationin a liquid medium.

This invention further relates to new and improved in vitro diagnostics(IVDs) assays which can detect disease at the molecular level i.e.,chemical and biological assays, including nucleic acid based assays(molecular diagnostics).

The invention also relates to chemical synthesis procedures that utilizea sequential process where products of a reaction are built up through aseries of addition and removal steps to produce a final product,additions of amino acids or synthesis of nucleic acid polymers, and theremoval of reaction products not bound to the movable particle orsurface.

It further relates to determination of antigens, antibodies and otherproteins on blood cells, in blood serum and other bodily samples and theuse of buffers and other liquids in the determination process.

The invention further relates to blood banking immunological diagnostictesting and immunohematology and more particularly to blood cellserological testing using magnetic particles and magnets to separatebound entities to be measured from unbound entities.

It further relates to determination of antigens, antibodies and otherproteins on blood cells, in serum and other bodily samples and the useof buffers and other liquids in the determination process.

It further relates to cell separation procedures common in cancerresearch, diagnostics and therapy, and in flowcytometer and cell sorterapplications for counting or harvesting particular cell types.

BACKGROUND OF THE INVENTION General Background

Clinical and industrial laboratories and chemical manufacturing plantsrepresent an enormous, widespread industry in which many procedures andprocesses require, or are significantly enhanced by, separation of aknown or unknown material of interest from materials in the processwhich are not of interest, and which may interfere with the goodperformance of the process.

Many of these procedures are assays performed to determine the amount ofa given entity in a sample which is present along with many otherentities. In the health and medical sectors, this includes, for example,the isolation, expansion and identification of genetic material, usuallyfrom body liquids or tissues, as well as the detection andquantification of antigens, antibodies, and other proteins and smallmolecules. On the environmental level it is desirable to determine theamount or presence of materials in water, air, chemicals, foods and thelike.

Modern-day immunoassays are a good example of the many and variedlaboratory and manufacturing procedures and processes that requirepurification of a material by separation from contaminants and othermaterials. Immunoassays in which small amounts of an analyte are soughtand measured in a sample, have evolved from the early, generallychemical, formats of various kinds of techniques. Binding partners,either specific for a given epitope or polyclonal in nature, have beenemployed in reaction with the desired target (be it known or unknown) toproduce an entity which can be detected through a label attached to itor through some discernable, measurable effect upon a component of thetest or on a substrate reactable with the label. Generally speaking,most, of the commercially useful versions of such tests require that thereacted binding partner be separated from unreacted binding partner soas to determine whether the sought entity has reacted or not reacted andhow much is present.

The need to separate reactants from interfering substances is a majordesign feature in immunoassays, blood bank procedures, and chemicalsynthesis procedures. Many variations on several separation or washingtechniques have been utilized, often involving dilution with largequantities of wash solution or sample, and often presenting the elementof the test which determines the ease, complexity, cost, overall time,and sensitivity of the test, as well as the design of automated assaysystems and the volume of hazardous material to be controlled anddiscarded. Immunoassays typically use both dilution and decanting orlateral liquid flow on chromatographic membrane or paper strip, withlarge quantities of diluent or sample as washing methods. If aconvenient separation method could be made available, alternativemethods would be more readily adopted. An appropriate alternativeseparation concept would be broadly useful for immunoassays, includingthe special case of immunoassays that are utilized in blood bankinginvolving cellular antigens and antibodies to them, and sequentialchemical synthetic procedures.

Dilution And Decant Wash Methods

Historically, the most common wash method in immunoassays, involves theimmobilization of a reagent antibody on a portion of the surface ofindividually coated containers, such as a microtiter well or test tube,then washing away undesired material by repeated wash solution additionsand decanting steps. When this method is used, the final reaction isobserved in the same tube or well that was washed with the possibilitythat any contaminating material attached to its sides or inadvertentlyremaining in the container would interfere with the specificity orsensitivity of the assay. Additionally, the discarded liquids are oftencontaminated with hazardous material. Similar problems are encounteredwhen the assay is done on a chromatographic paper strip.

Microsphere and Particle Methods for Separation

In many laboratory methods the material of interest is specificallycaptured on particles or microspheres as the solid state surface. Suchparticles or microspheres are employed in many and varied diagnostic andpreparative methods. Their primary purpose in these methods is toseparate or purify specific items of interest from unwanted surroundingcontaminating materials. Similarly, in blood bank red cell testing thered cell itself is the particle surface that captures material ofinterest. The active binding agents affixing such particles includeantibodies, ligands, lectins, oligonucleotides and many other specificbinding molecules of non-immune origin. Methods are well known andcommonly practiced which enable the preparation of particles andmicrospheres of various size, specific gravity, and other properties tobe attached to reagents which can specifically bind to specific cells,viruses and sub-cellular particles or other materials of interest.

When particles of various kinds are bound to materials of interest, theybecome much larger complexes which settle more rapidly under Stokes law.Larger denser complexes can be sedimented or centrifuged from a mixtureand thus washed. Unfortunately this method requires centrifugation tocreate force to move the particles, and the medium must have a lesserspecific gravity than the particles which restricts media that can beused and limits the power of the separation.

Variations of the dilution/decant wash systems are common. Many use asingle coated bead, or coated micro particles in the test tube whichtypically must be centrifuged prior to every decanting. Segregation ofmaterials with magnetic particles bound to a ligand or antibody thatselectively binds to an entity of interest is in wide use for purposesof separation or segregation. However, these methods usually requirefixation on a surface and physical washing by flow of washing liquidrequiring decanting or control of liquid flow with pumps and valves,adding considerable complexity to automated instruments and mechanicaland robotic systems. Thus, when coated magnetic particles are used, theapplication of a magnet to the side of the tube before each decantingstep is required.

Magnetic Particle Wash Methods

Some current separation methods use, as an alternative tocentrifugation, separation by a process in which magnetic particles arebound specifically to the materials of interest to form a complex whichis then selectively separated from materials not of interest by the pullof a magnetic field rather than by centrifugation or by gravity alone.Usually the material to be separated is pulled to the side of the vesselby magnetic force and the material not of interest removed by decantingor rinsing or other liquid flow past the material of interest held onthe wall.

Lateral Flow Wash Methods

A current art-preferred method of conducting a wide variety of assaysinvolves the use of individually coated chromatographic strips whereby asample suspected of containing the analyte sought to be determined isapplied either alone, or with appropriate reagents, to a chromatographicmembrane or layers of membranes and allowed by lateral flow to come intocontact on the strip with previously immobilized materials. Depending onthe nature of reactants chosen, the immobilized reagents act to separatethe desired test components so that a proper determination of thepresence of the analyte can be made. This procedure typically passes thesample and labeled reagents laterally along a chromatographic strip andinto the binding zone to bind with an immobilized reagent. Non-specificbinding material to the immobilized reagent or to the strip is to beavoided or eliminated and therefore sufficient wash liquid must passthrough the zone to remove unbound material.

While, in general, lateral flow methods have the advantage ofeliminating centrifugation steps and much of the liquid handling stepsrequired for washing reactants in other methods, many lateral flowmethods involve reagent addition steps during the procedure. Forexample, Becton Dickinson ColorPac® lateral flow devices may requirepipetting of as many as six reagents during an analytic procedure.

An alternative chromatographic strip technology has been described inU.S. Pat. Nos. 6,713,271 and 6,136,549 assigned to Wavesense LLC ofLaguna Beach, Calif. In these two patents, magnetic assay methods andsystems are described in which uniform bulk-prepared microparticlereagents and liquid reagents are substituted for the immobilizedmaterials commonly used on the strip. Instead, magnetic particle-taggedreagents participating in the test and flowing on the strip are capturedand held at a desired site on the strip by a magnet field applied to thesite. The captured particles are read to determine the presence orabsence of the analyte sought. Large volumes of wash liquid are requiredto move sample and unbound reactants away from the observation zone.

Density Gradient Wash Methods

Density gradient separation is a commonly used separation method thatemploys a density gradient column and centrifugation. Density gradientseparation methods separate materials of a mixture based upon theirdensity. Materials of different density will spin down undercentrifugation until they reach a liquid media layer of equal specificgravity. They “float” and do not enter the regions of density equal orhigher than their own.

Separation based on the rate of sedimentation of particles through adensity gradient to separate them from materials with a lower specificgravity that will either float on the density gradient or move to adifferent layer in the gradient or sediment at a slower rate than thelarger particles has been used for blood bank serological testing. Inthis method, cells are forced by centrifugal force through a solution ofintermediate density which allows the heavier red blood cells to passthrough and floats the less dense serum on the top. The washed red cellscan either be recovered following a decant step or be assayed in placeby incorporation of a reagent into the solution of intermediate density,eliminating the need for a decant step.

Sequential Chemical Synthesis Background

Industrial chemical synthetic procedures often require the removal ofreactive materials prior to the sequential addition of the nextreactant, and then the removal of that reactant prior to the addition ofthe next reactant. Thus, separation and wash procedures play a majorpart of determining the physical manipulations required in a syntheticprocess.

Blood Transfusion Background

Blood Banks collect more than 15 million units of blood annually formore than 14 million transfusions in the United States. Pretransfusiontesting of patient and donor blood samples is an enormous industrydistributed over nearly 10,000 large and small blood bank laboratories.

Blood Banks test to determine the blood type of red blood cells ofdonors and patients, to detect antibodies in blood sera, and performcompatibility (crossmatch) tests and for potential infectious diseaseagents in every donor blood sample.

The following blood bank tests are among the most important and mostfrequently conducted tests:

-   1—Direct red cell antigen testing, typically ABO grouping and Rh    typing-   2—Reverse grouping (testing for antibodies in serum which react with    A or B cells)-   3—Antiglobulin based tests which require a serum protein removal    step as a part of the procedure. These include indirect typing    procedures for antigens (such as Kell, Duffy, Kidd and some Rh    procedures), direct antiglobulin test (test for serum proteins on an    individuals' red cells), indirect antiglobulin tests (includes    antibody screening, antibody identification and the crossmatch).

The following is a description of common blood bank reagents andtechniques.

Blood Bank Reagents and Techniques

THE DIRECT COOMBS (Antiglobulin) TEST: The direct Coombs (antiglobulin)test, which is used in the investigation of anemias, will demonstratewhether red blood cells are coated with incomplete antibody, especiallythat of babies born to Rh-negative mothers. It will reveal whetherantibodies have been adsorbed on the surface of the red cells while thebaby was in the uterus and is important in diagnosing Rh hemolyticdisease of the newborn. The direct Coombs (antiglobulin) test isperformed by washing the red blood cells to be tested and attempting toagglutinate them with Coombs (antiglobulin) reagent. The Coombs reagentis widely available. This test, as well as the indirect test describedbelow, are variously referred to herein as Coombs test, anti-globulintest, AHG test or variations thereof. The serum is variously referred toas Coombs serum, anti-human globulin serum, AHG serum or the like.

THE INDIRECT COOMBS (Antiglobulin) TEST: The indirect Coombs(antiglobulin) test is used to screen the patient's serum for atypicalantibodies such as Rho (D), Kell (K), Duffy (Fya), and hr′ (c). Thepresence of any of these atypical antibodies can cause hemolytic diseaseof the newborn or transfusion reactions.

In the indirect test, an unknown serum is tested with human group Oreagent red blood cells. Group O reagent antibody screening cells areavailable commercially. They are a group of two or three O Rh positiveand Rh negative donor red blood cells selected so as to be positive onat least 50% of the cells for each of the common clinically importantred blood cell antigens. If a serum gives a positive reaction with suchscreening cells, tested separately or as a mixture, it must contain anatypical antibody of unknown identity. The techniques involved inperforming the direct and indirect antiglobulin and the reasonstherefore, are well-known in the art.

ABO GROUPING: Red cell (forward) typing with anti-A or anti-B reagentswill demonstrate the presence or absence of A and B antigens on the redcell. Serum (reverse) typing with reagent A and B red cells willdemonstrate the presence of anti-A and anti-B in the serum.

OTHER REAGENTS USEFUL IN ABO GROUPING: Other reagents may be usedroutinely in ABO grouping. They are often essential for resolvingdiscrepancies between forward and reverse typing. Blood is not usuallyreleased from the blood bank for transfusion until any suchdiscrepancies have been resolved. Anti-A, B (Group O serum) can detectweak A variants that may be missed by regular anti-A reagent. Otherreagents: Anti-A, B reagent (Group O serum), Anti-A₁ reagent (absorbed Bserum or Dolichos lectin), Anti-H lectin (Ulex), Reagent O Rh-positivescreening cells, Reagent A₂ cells.

COMPATIBILITY TESTING: Crossmatch (compatibility) tests are performed todetermine the suitability of the donor's blood for the particularrecipient. Blood transfusions are not given before performing a majorcrossmatch to test the donor's red cells against the serum of therecipient. If both donor and recipient are of the same blood group, aminor cross-match may be done to test the recipient's red cells againstthe donor's serum. The minor crossmatch is of no value when donor andrecipient belong to different blood groups because agglutination willoccur . Major Crossmatch involves mixing donor's red cells withrecipient's serum, centrifuging at 37° C. and adding antiglobulinreagent. Minor Crossmatch involves mixing donor's serum with recipient'sred cells, centrifuging at 37° C. and adding antiglobulin reagent.

RH TYPING: The crossmatch makes it possible to avoid hemolytictransfusion reactions following a particular transfusion. Blood banksare also concerned about isosensitization. If, for example, a blood bankselects Rho (D)-positive blood for an Rho (D)-negative woman, she willnot have an incompatible crossmatch or a transfusion reaction if she hasno anti-Rho (D) antibodies in her blood, but she may become sensitizedto the Rho (D) antigen. Initiation of the immune response presentsproblems for subsequent transfusions and for subsequent pregnancies ifshe has an Rho (D)-positive mate. Rho (D) negative donors, Rho(D)-negative women and their Rho (D)-negative mates, and Rho(D)-negative cord bloods are tested for the presence of Rho\variant (DU)antigen that may not always be detected by the anti-Rho (D) slide test.Various Rh typing methods and the appropriate controls are well-known tothe art.

ANTIBODY TESTS: Screening for antibodies is especially important forpatients receiving blood and the obstetrical patient. In obstetricalpatients, early detection allows time to prepare for possibleintrauterine or exchange transfusion in cases of Rh hemolytic disease ofthe newborn. Once the presence of an antibody has been detected, theproblem of its identification remains, but this has been simplified bythe development of antibody identification panels of group O reagent redcells. These screening and identification methods are well known tothose skilled in the art.

Most blood bank tests require a wash step during the procedure. Thecentrifugal washing step, either by dilution and decant or sedimentationinto beads or gel takes about 5 to 10 minutes. The indirect antiglobulintest (IAT) is the most used and most reliable test in blood banking todetermine binding of antibodies to red blood cells. This test isperformed manually in test tube, requires addition of red cells andantisera, three manual centrifugation and decanting steps and finally acareful evaluation under the microscope by a skilled technologist ofwhether the red cells have agglutinated, and recording of results. It isvery labor intensive.

Although red cells in the presence of appropriate antibodies may clumpin the absence of centrifugal forces, centrifugal procedures aretypically used for almost all blood bank serological assays to causeenhanced aggregation of red cells for naked eye visualization at theassay end point. This is a major cause of a need to repeat an assay.

Classically, blood bank methods for determining blood types or detectingred cell antibodies in donor or patient sera are done manually in alarge percentage of blood banks and rely upon hemagglutination as theendpoint to determining whether red cell antibodies have reacted withred blood cells in donor or patient blood samples.

Blood bank testing procedures have historically been a somewhat specialcase in the immunosassay art because the red blood cell, which is notvisible to the naked eye, can form small aggregates that are visible tothe naked eye and have a pattern distinguishable from that ofnonaggregated red blood cells. Thus the typical blood bank procedurerelies on human pattern recognition to detect a reaction. In blood banktesting, a wide variety of tests are performed using classical,traditional wet chemistry techniques.

In recent years the manual DiaMed-ID (D-ID) antiglobulin gel test (OrthoClinical Diagnostics, Raritan, NJ) has largely replaced the classicalmanual method. It requires a ten minute centrifugation step and a morestraightforward manual reading.

More and more testing is now being performed on automated instruments.For example, the Ortho Pro-vue (Ortho Clinical Diagnostics, Raritan,N.J.) is an automatic gel technology system, while the ABS200 andGalileo instruments (Immucor, Norcross, Ga.) and the Olympus Tango andOlympus PK700 blood center instruments (Olympus, Mellville, N.Y.) areother large volume systems. All three instruments requirecentrifugation.

There are other blood bank laboratory and forensic laboratoryapplications where it is important to detect the presence of a minorpopulation of red blood cells from a second individual in a sample ofblood belonging to the first individual, such as athlete blood doping.

This test is valuable in assaying the survival of transfused blood fromvarious donors, as a biological compatibility test, multiplexingcross-matching of many donors with a patient(s) in one reaction vessel,antibody screening with multiple cells, research investigation of rarered blood cell chimeras and other special situations, in addition todetecting fetal red blood cells in a sample of maternal blood from an RhNegative mother.

Fetal Maternal Hemorrhage Background. One special case for use of theinvention in a blood bank laboratory is the test to detect FetalMaternal Hemorrhage (FMH) in pregnant Rh negative mothers. This test hasbecome very important in the field of perinatal medicine and testmethods currently available are far from ideal. The invention can bereadily adapted to detect and quantitate fetal red cells in bloodsamples from Rh-negative mothers and do so in a superior manner.

During pregnancy the blood circulations of mother and baby are separateand do not mix. However, some leakage of small amounts of blood from thebaby's circulation into the mother's circulation is usual in almostevery pregnancy and is known as Fetal Maternal Hemorrhage (FMH).Diagnostic tests to detect and measure the amount of baby's blood in themother's blood sample are very important in the case of an Rh negativemother pregnant with an Rh positive baby. In these cases RBC leakagefrom an Rh positive fetus to an Rh negative mother, i.e., fetal maternalhemorrhage (FMH) occurs late in pregnancy and during delivery may causeRh immunization of the mother. This will cause consequent HemolyticDisease of the Fetus and Newborn in her future Rh-positive babies. It isthus, very important to screen for and detect such occurrences.

The current screening test is a commercially available kit which employsmixed field detection in which any baby's red blood cells in themother's blood sample form “rosettes” which are seen under themicroscope and counted by a technologist.

The currently used quantitative test for fetal red blood cells inmother's blood, the Kleihauer-Betke fetal cells stain and manual count,is used when the screening test is positive. It is sensitive to lessthan 0.1 ml of fetal cells in the mother's circulation and isquantitative. However, the Kleihauer-Betke test is not entirelysatisfactory since because it is manual, time consuming, requires skilland care, involves a technician training and competency assessment, usesunstable unpredictable reagents, is prone to false positive and falsenegative results and is very imprecise.

There is thus, an unmet need for a FMH test that is rapid, economic andperforms both screening and quantitative functions, and is objective inthat it gives a numeric result free from the subjectivity of thetechnologist's interpretation or rosette counts in a microscopic field.

SUMMARY OF THE INVENTION

The invention comprises reagents and methods for separation of materialsof interest from materials which would interfere with the test fromother contaminating materials not of interest called collectively hereinMNOI or materials not of interest, in a continuous fluid medium throughthe forced movement of materials of interest through at least one fluidzone but preferably a multizone liquid medium into certain zones, whichhave specific gravity and other properties selected to deter the entryof unwanted materials. Materials of interest, in the movable complex,are forced into contact with a reactive surface capable of binding thematerial of interest and holding it to the surface. When the initialmovement force is removed, a second opposing buoyant force causes theremoval of the unbound material from the surface by floatation.Following the floatation removal of unbound material, the reactivesurface is observed for the complexed material of interest.

The invention can be described generally as the use of:

-   -   1. magnetic particles attached to a binding partner (Mag.BP) of        usually a Material of Interest (MOI).    -   2. a reaction of the Mag.BP particle reagent with the MOI    -   3. a force, such as a magnetic field for moving reacted MOI.    -   4. a movement of MOI from a zone or through multiple zones in a        continuous liquid medium,    -   5. specific capture of MOI on a surface    -   6. an application of a counterforce, such as flotation by        removal of the magnetic force, or the application of an        additional magnetic field in the opposite direction.

The term magnetic is also meant herein to include paramagnetic. Thepreferred method of the invention employs a magnetic field as the movingforce. The buoyancy effect on the MNOI or interfering materials iscaused by their natural tendency to float on the underlying, more denselayers. The objective is to move only the materials of interest complexinto one zone where they may be read or measured and leave interferingmaterials floating in a different zone where they will not alter thereading step. This preferred method of forcing differential movement ofcomplexed materials of interest, but not of materials not of interest isby tagging the MOI with magnetic particles bound to an MOI bindingpartner and directing their movement with a magnetic field through oneor more contiguous layered fluid zones with higher specific gravity.Flotation of lighter materials prevents unwanted materials from enteringdenser zones onto which the magnetic field forces MOI Preferably, zonesare layered and remain layered on the basis of non-miscibility andspecific gravity, and materials of interest are subjected to the forceby the presence of the magnetic particles. They are moved through thezones by the force of a magnetic field. Thus, it can be seen that themagnetic particles are attached to a key reactant which binds to theMOI, or to a material (a cell for example) that can bind to the MOI.

Some of these delivery destination areas may have specific capturemechanisms, such as surface attached antibodies or other ligands whichbind the MOI. after the magnetic field is removed. Other embodiments ofcapture make use of the properties release after the magnetic field isremoved. Controlled gentle consistent release may be obtained by thusapplying a flotation counterforce, by utilizing a layer of greaterdensity than the complex as the last fluid zone or introduction of adense layer into the vessel at read time, which will sink to the bottomand float off any material not actively bound to the floor, leaving thebound material alone to provide a clean signal.

The invention contemplates a new series of reagents which function in aliquid medium. In particular, the specific gravity of the magneticparticles and the separating zone are matched so that the magneticparticles alone or complexed have a lower specific gravity than theseparating zone adjacent to the capture binding surface. This assuresthat the particles and complex will stay in suspension in a zone layerwith a matching specific gravity and will not sediment out of thatlayer, without the application of magnetic force. Application of amagnetic force to the MOI complex to move it to the binding surface, andthe subsequent removal of the magnetic force after they have beendeposited on the surface will result in the separation by flotation ofany that are, not specifically bound by the MOI—binding surface complex.

The zones may contain appropriate reactants which cause chemical orphysical processes to occur before materials are moved on into the nextfluid zone. The invention is characterized generally by moving theparticles through the liquid media rather than flowing liquids over theparticles.

The invention applicable to many scientific, clinical and industrialareas including in vitro diagnostic (IVD) testing including blood bankpretransfusion testing, cell separation, microscopy, chemical synthesisin many fields from cancer research and diagnosis to chemicalmanufacturing.

Importantly, the invention simplifies nearly all of the scientific,clinical and industrial procedures and processes that require separationand purification of materials of interest from contaminating orinterfering materials not of interest. Simplification comes largely fromthe elimination of centrifugation as a necessary step in the prior artand elimination of the need for fluid handling required for washing awaycontaminants, including reservoirs, pumps, tubing, valves and electroniccontrols that currently complicate instrument and equipment systemscurrently used in such procedures and processes.

The present invention is useful in performing virtually all tests thatare performed in the blood bank winch Involve reactions between bindingpartners, such as immunological binding partners or universal bindingpartners such as lectins, biotin-avidin, Protein A or G, ligands andtheir receptors and the like. As so applied, magnets and magneticparticle-labeled reagents are used to capture and/or release magneticparticle-tagged entities for immunohematology diagnostic testingpurposes. The magnetic tagged entities may be, depending on theparticular assay, any of tagged antibodies, tagged blood cells, taggeduniversal binding partners, especially rod blood cells, binding agentssuch as lectins, biotin-avidin, Protein A or G, ligands and theirreceptors and the like.

In this aspect, the invention utilizes magnetic particles directlylabeled with antibody (such as anti-A, anti-B, anti-D or anti-humanserum). With such reagents used in the assays of the invention, the redcells will only react with magnetic particles if the red cells have thereactive antigen corresponding to the specific antibody on the particles(and in the case of anti-human serum, have been washed clean of serum).In these assays, the presence of an RBC on a magnet, is a positive eventfor the presence of the antigen sought and can be seen because of thehemoglobin in the cells.

Another reagent used in the invention are magnetic particles labeledwith a red cell binding partner, i.e., a lectin or other universal redblood cell binding material (in effect an anti-RBC). The lectin or otherbinding molecule should be able to bind magnetic particles to all humanred blood cells regardless of blood group, and must not react withCoombs serum or other human antibodies. The magnetic particles are usedto move the RBCs through zones or are positioned at a location on achromatographic strip so that fluids can move by the cells (i.e., thefluids move over the comparatively stationary cells). In this moreuniversal format, a labeled AHG reagent, not bound to a magnet, butlabeled with a detectable indicator such as an enzyme, fluorophor, andthe like, described in more detail below, is used to react with themagnet bound red cell complex and any bound serum antibody.

The invention also may employ software to sense the progress of theprocess to provide feedback to timing of incubation, reagent dispensing,order, amount of reagent dispensing, application or removal of magneticfield and the like.

The invention is not restricted to magnetic field forces and flotationcounterforces. Other types of forces are employed in other embodiments.For example, sedimentation under gravity or centrifugation orelectrophoresis or simply depending on the natural properties of thematerials and fluid zones, such as density may be used to achieveseparation. Thus, the invention envisages many variations on the generalmethod of differential entry of MOI and MNOI into and through zones in acontinuous fluid medium. Such variant methods may, among others, alterthe relative strengths of force and counterforce by varying the strengthand direction of magnetic fields by varying the size of magneticparticles, by varying flotation force, by varying the specific gravityof fluid zones and employing and/or several different color labels totag several MOI in a separated subset. One particular class of magneticreagent is a magnetic particle tagged with a very light flotationmoiety. This class of mag-reagent is able to form a mag.antibody.analytecomplex of specific gravity less than 1.0, allowing the sample itself toact as the repugnant dense layer. It is apparent to one skilled in thestate of the art that magnetic particles can be made floatable inaqueous solutions by coating them with polystyrene microspheres. Thepreferred forces of the invention however are the magnetic field to movethe magnetic particles and flotation as by removal of the magnetic fieldto separation MNOI. The intensity, direction and timing of the magneticfields may change as suited to the steps of the procedure.

The invention envisages a new series of fluids employed in novel layersto obtain the necessary properties to exclude entry of unwantedmaterials including non-miscibility, specific gravity, chemicalreactivity or inertness. These will be required by the various methods,procedures and processes now made possible by the invention.

Readable labels such as enzymes, fluorophors, chemiluminescentmaterials, radioactive isotopes, and other labels may be attached tomaterials of interest and they may be delivered to a final zone forreading or harvesting. Such reagents may be preintroduced intoappropriate zones during test kit manufacture so they will react onlywhen materials of interest traverse that reagent zone.

The invention includes delivery of selected materials of interest to areading zone where they may be detected and measured. They may also bedelivered to a harvest area where highly purified materials may becollected for further use. In the case of cells, they may be deliveredto a microscopic slide to other surface for counting, staining andmicroscopic examination, to cell media for cell culture, or formolecular studies such as PCR.

DETAILED DESCRIPTION OF THE INVENTION

The invention comprises unique novel reagents and methods for separationof materials of interest from interfering materials or contaminatingmaterials not of interest in a continuous single or multizone liquidmedium. For example, in many industrial and laboratory procedures, suchas assays or chemical syntheses, it is necessary to separate reactantsfrom non-reactants especially when the separation is beneficial ornecessary for the success of subsequent assay steps. For this purpose,separation of reactants from non-reactants or interfering substances,the invention utilizes the forced movement of selected materials throughdifferent zones of a continuous single or multizone liquid medium whereonly certain desired materials of interest are caused to move into orthrough the zone or zones. Depending on the particular assay orprocedure being performed, the materials not of interest need notnecessarily be separated if their presence does not interfere with thequantitative or quality measurement of the material of interest.

The invention utilizes a vessel or an array of vessels such as amicrotiter plate containing a continuous liquid medium which is dividedor layered into at least one but preferably more than one discreteliquid zones with different physical or chemical properties. Theinvention is based upon forced movement of selected particles throughthis continuous but multizone liquid medium. The zones or layers of theliquid medium are designed chemically and or physically to reject orsignificantly retard, entry of materials not subject to the force, or toapply a counterforce to MNOI. On the other hand, materials of interest,rendered subject to the force, can be forced to enter and pass throughcertain zones that they would not normally enter, or that they would beretarded from entering. In certain cases, the force will overcome anycounterforce that applies to MOI. In this manner MOI can be isolated andpurified of all contaminants and delivered to a reading or harvest zone.

The method specifically takes advantage of:

-   1. a purposefully designed zone or multiple zones, in a continuous    liquid medium-   2. magnetic particles,-   3. a magnetic field force-   4. a buoyant force-   5. a capture surface.    There are many and varied assay formats which may be used to take    advantage of the present invention. Following are some general    methods.

In the preferred embodiment, zones are layered and remain layered on thebasis of one or more of poor or non-miscibility, differing viscositiesor surface tensions, hydrophobicity, hydrophyllicity and specificgravities. The materials of interest are treated with a binding partnerto which magnetic particles are bound and then moved as a reactedcomplex through the zones by the force of a magnetic field. In manycases, materials of interest, even when complexed can be forced intozones of density greater than that of the materials themselves, i.e.zones in which they would not have entered but for the application of aselective force.

The inventive methods are applied to immunoassays in general, tovirtually all blood bank assays and to sequential chemical synthesisprocedures involving the synthesis of compounds through the separationof intermediates prior to the next reaction step. They are applicable tothe purification of cells, particles and molecules from complexmixtures.

Importantly, the invention eliminates the need for centrifugation andallows immunoassays to be performed without extraneous wash steps anddecanting or rinsing steps. This simplifies the design and functionassay instrumentation and automation, as well as the containment ofhazardous materials in the reaction vessel.

As noted in this Specification, this Application is a Continuation ofU.S. Ser. No. 11/715,411 filed Mar. 8, 2007 which is aContinuation-in-Part of U.S. Ser. No. 11/518,189 filed Sep. 11, 2006which claims the benefit of U.S. Provisional Application 60/716,591filed Sep. 13, 2005, said U.S. application Ser. Nos. 11/518,189 and11/715,411 being incorporated herein by reference for all purposes asthough repeated herein verbatim in their entirety, claims and abstractincluded.

In the preferred embodiment, materials of interest that are to beassayed, purified or processed are rendered magnetic by the attachmentthereto of a magnetic particle tagged binding partner of the material ofinterest the preferred moving force is a magnetic field and the zonesare layered on the basis of density and non-miscibility. Moreparticularly, magnetized target reactants are moved by a moving magneticfield from the fraction of the reaction mixture into a layered zone ofspecific gravity greater than any of the reactants and specific gravityof the solute mixture. Materials of lower specific gravity are excludedfrom entering the dense layer by the phenomenon of flotation; theysimply float on the surface of the dense layer according to Archimedes'principle unless purposefully forced under by applying the appropriateforce, thus becoming separated from materials of interest that have beenmoved under by the magnetic force. Because flotation is absolute, thisresults in ultra clean separation, which is often very desirable in manyprocedures.

As can be seen from the above, this invention is directly applicable toany immunoassay where it is necessary or desirable to provide one ormore separation steps during the assay, such as in separating bound andunbound materials from a complex prior to the detection step. Forexample, in a sandwich assay such as for HBsAg or B-hCG, an antibody tofirst determinant (Ab₁) on the antigen is tagged with magnetic particlesand a second labeled antibody to a second determinant (Ab₂) is mixedwith the sample. Following incubation, a complex of theMag.antibody.antigen.second antibody with label is formed. The labeledantibody attached to the complex is separated from any unbound labeledantibody by the application of a magnetic field which moves of themagnetic particle complex through a more dense layer to a detection zonewhile the unbound labeled antibody floats to the top of the zone.

The method also applies to the ToRCH Assays, i.e., Toxoplasmosis,Rubella, CMV and HSV. In this case, the disease related antigen (i.e.Rubella hemaglutinin antigen) is bound to the magnet, any antibody toRubella antigen in the patient's sample reacts with the antigen on themagnet and then is separated from the unbound IgG in the sample bymoving the complexed particles through a separating zone and intocontact with a labeled antiglobulin reagent which reacts with patient'srubella antibody if present.

Examples of the invention in several applications

Some examples with varying combinations of previously describedrequirements will now be given before exploring more detailed aspectsand issues of the invention: These methods include utilizing:

-   1—two continuous liquid zones, the first zone being or comprising    the sample liquid and particulate reactants and the second zone    being a liquid zone with greater specific gravity than the    reactants.-   2—binding partner coated with magnetic particles wherein the binding    partner is a capture antibody to MOI, or a lectin that can react    with tagged red blood cells (Example 1), or magnetic particles    coated with an antigen from an infectious agent such as HIV or    Hepatitis C (Example 2).-   3—magnetic field to move particles.-   4—buoyant force to move particles.-   5—a capture surface zone coated with an antibody (anti Human IgG in    the examples) reactive with the material of interest in the complex    (human IgG in the Examples).

EXAMPLE 1

Blood bank indirect antiglobulin test for crossmatch, antibody detectionor indirect typing With a human typing reagent substituted for patientserum. A microtiter plate with the bottom of the wells coated with mouseanti-human IgG antibody is provided. A separating zone is placed on thebottom of the wells. A suspension donor or reagent of red cells andpatient serum and magnetic particles coated with a universal red cellbinding reagent such as a lectin or mouse anti-human red blood cellantibody. (Note: to simplify pipetting addition steps and increase theserum-red cell ratio, the red cell suspension may be pre-tagged with themagnetic particle). After appropriate mixing and incubation, themagnetic particle complex is moved through the separating zone by amagnetic field and on to the anti-human IgG antibody coated onto thewell surface. The magnetic force holding the complex against the bottomof the well is released and the cells not bound by the anti human IgGreagent allowed to float or be agitated off of the bottom. The visibleattached red cells indicate a positive crossmatch.

EXAMPLE 2

Test for Antibody to HIV or to Hepatitis C virus (HCV) or to cytomegalovirus (CMV).

The bottom of the well is coated of a microtiter plate with mouse antihuman IgG antibody and overlayed with a separating zone. Patient serumis added and magnetic particles coated with an antigen from theinfectious agent of interest is added. After appropriate mixing andincubation, the magnetic particle-antigen-human antibody (if any)complex is forced through the separating zone and on to the anti humanIgG antibody coated surface. After reaction (if any) with the IgGantibody, the magnetic force holding the complex against the bottom ofthe well is removed to allow complex not bound by the anti human IgGreagent to float or be agitated off of the bottom. Measure any attachedparticles.

EXAMPLE 3

Sandwich Test for Antigen. The bottom of a microtiter well is coatedwith one antibody to a determinant on the antigen and the magneticparticle is coated with another antibody to the antigenic determinants.The specific gravity of the magnetic particle (for example 1.1 to 1.3),the suspending liquid (for example 1.0 to 1.15) and the sample (forexample 1.0 to 1.15) are less than the specific gravity of the denseseparating liquid (for example 1.3 to 2.0). The magnetic particlesthemselves can be used as both a reactant and a label. All reactants andseparating liquid can be in the vessel prior to the addition of thesample and because of the orientation of the vessel and the specificgravity of the liquids and magnetic particles maintain the order fromtop to bottom, magnetic particles, separating liquid, antibody coatedvessel bottom when the less dense sample is added and mixed with themagnetic particle suspension in the top sample and magnetic particlezone. Following incubation the magnetic particles complexed with theantigen (MOI) if present, or not complexed with the antigen if absent,are moved by application of a magnetic force through the denseseparating liquid and to contact with the antibody coated vessel bottom.The magnetic particle-MOI-antibody complex will form if the MOI ispresent in the sample. The magnetic force is removed and unboundmagnetic particles will float off the bottom surface because theparticles are less dense, more buoyant, than the separating liquid.Observe the bottom reaction surface for the presence of bound magneticparticles and detect those bound particles.

EXAMPLE 4

Pregnancy test—This example can use the standard separating zone inaddition to the sample zone or utilize only one separating zone, theurine sample itself. The magnetic particles are used as the label inthis test. The test vessel contains a reactive surface coated with afirst antibody to hCG, and a magnetic particle of low specific gravitycoated with a second antibody to hCG. Add the sample to the vessel,mixing the less dense magnetic particles with the sample, apply amagnetic field to force the magnetic particle hCG complex through theseparating zone (urine sample) onto the reactive surface. Remove themagnetic force holding the complex against the bottom of the vessel andallow the unbound complex to float, agitated or decanted off thereaction zone. Measure or observe the attached particles.

EXAMPLE 5

Pregnancy test with a direct label.—A vessel, or a microtiter platearray of wells, with a dense separating zone in place at the bottom. Addfirst a labeled antibody specific for the analyte, then a secondantibody [specific for the analyte] attached to magnetic particles. Thenadd patient urine sample. After appropriate mixing and incubation, applya magnetic field to force the magnetic particle complex through theseparating zone to the bottom of the well. Measure the attached label.

EXAMPLE

Pregnancy test With indirect label. A vessel, or a microtiter platearray of wells, with a dense separating zone in place at the bottomcontaining a substrate for an enzyme, and an intermediate separatingzone above the substrate zone is provided. Add a first antibody labeledwith an enzyme and a second antibody attached to magnetic particles andpatient sample. After appropriate mixing and incubation, force themagnetic particle complex through the separating zone and into thesubstrate zone. After waiting the appropriate time measure the substratethat has been converted to product by the enzyme label. Measure theproduct developed.

EXAMPLE 7

Direct Blood typing—In a vessel or micro titer plate with a denserseparating liquid zone such as a fluorochemical or an isotonic Ficoll®solution in place on the bottom of the wells, add a saline suspension ofred blood cells and a magnetic particles coated with specific red cellantibody, for example anti A, to an antigen that may be present on thered cells. After appropriate mixing and incubation force the magneticparticle complex through the separating zone and measure any attachedred cells, obtaining the signal by absorbance measurement of hemoglobinor the hemoglobin signal enhanced with benzidine.

EXAMPLE 8

Blood blank or cell antigen detection using a sequential approach. In amicrotiter plate with a separating zone on the bottom and a labeledantibody zone above that and another separating zone above the labeledantibody zone add cells and a capture antibody specific for a cell typebound to a magnetic particle. After appropriate mixing, force thecomplex through the top separating zone and into the labeled antibodyzone and ultimately through that zone and through the bottom separatingzone. Measure any attached label in the complex at the bottom of thewell.

EXAMPLE 9

Synthetic Processes of either research or commercial scale. For someprocesses or systems it may be desirable to have one single separatingzone beneath multiple reactant containing zones that are separated fromeach other by baffles extending into the separating zone. For example,consider a bottomless microtiter plate partially immersed in a traycontaining a liquid separating zone such that the separating zonecreates the “bottom” of each microtiter baffled zone. Place variousreactants in each of the microtiter wells and move reactants from onewell to another well through the separating zone. This description isnot intended to limit this description to small volume baffledcontainers as described but also applied to very large baffled systemswith a common separating zone or zones.

EXAMPLE 10

A Typical Competitive Binding Assay A sample of serum which containsdigoxin, is treated simultaneously with digoxin antibody tagged withmagnetic particles and digoxin reagent binding partner of the antibodyof the Mag.antibody reagent, said binding partner being labeled with anenzyme. A competitive reaction occurs with the sample digoxin and thelabeled digoxin competing for combination with the Mag.Ab reagent. Thereaction products, Mag.Ab.Ab and Mag.Ab.Ag. are formed. After thereaction, the magnetic particles are subjected to a magnetic field forceto pull them through a liquid medium denser than the unreactedcomponents. As they travel, enzyme labeled digoxin particles not boundto containing the magnetic tag will either stay in solution or float tothe top of the dense layer and the enzyme label bound to the magneticparticles is moved to a substrate zone. The determination of thepresence and quantity of digoxin is then measured by evaluation of thereacted labeled digoxin reagent in accordance with known, competitivebinding protocols.

Introduction of samples. In general, samples to be studied or processedwill be introduced onto the top layer where they may react for a timebefore the next step moving certain reactants selectively down into andthrough more dense layers. Thus, it may be important that this topsample introduction layer be of lower specific gravity than the nextlayer below. In this regard, since some magnetic particles have a highspecific gravity, it may be necessary in the case of some reagents tocoat particles to adjust their buoyancy to make sure they remainsuspended in the top layer until forced down. Those skilled in the artare aware of the procedure for doing this. Even if the particles are ofa density that would sink without mixing they can be mixed in thesample-containing solution, by proper selection of the separatingsolution so that it is more dense than and immiscible with the samplecontaining solution. The amount of contact time between the captureparticles and the sample can also be controlled by adjusting volumes,viscosity, time of addition and other parameters.

Enhancing and speeding reactions by mixing. Oscillating magnetic fieldsor ultrasound pulses focused on a particular zone to cause particles tomove with rapid movements or oscillating motions over a short distance.Such movement or oscillations may be used when reactions are going on toenhance and speed reactions in particular zones and may also be used tofree materials not of interest from contaminants that are absorbed ontobut not bound to the mag-particles, so they are released and become freeto float back up into less dense layers above. It is also possible toapply mechanical mixing forces, such as the use of rotator platforms, tocause gentle mixing within zones but not between zones.

Zones. Design and selection of the separate zones in the continuousliquid medium may be selected based on the specific gravity of thereactants, sample medium, and reaction product of the test to theinvention. The multiple zones of the liquid medium may differ from eachother in various ways, such as their density or miscibility or surfacetension or hydrophobicity or hydrophyllicity, and are designed for eachlaboratory procedure or industrial process so that certain entities canbe selectively forced to enter and or pass through a particular zonewhich other materials will not or cannot enter, either on the basis oftheir natural properties, such as density, or on the basis of a propertyacquired from a particular treatment.

Zones may be chemically inert and designed simply based on theirphysical properties such as for example specific gravity and interfacialtension to exclude particular materials. In certain cases, the zones maycontain reagents or other substances that react with materials ofinterest and transform them in an intended fashion as they pass througha particular zone of the continuous liquid medium. The separatingsolutions can range from the extremely inert and dense fluorochemicals,oils, and organic solvents, to aqueous solutions of various pH with orwithout additional reactants contained in them. To aid those skilled inthe art in selection of separating zones, consideration should be givento the known or measured specific gravities of known materials all inconsideration of the densities of the materials involved in the test.For example, acetone and benzene have a density below 0.9, manysolutions of materials dissolved in water can be adjusted to densitiesfrom 1.0 upward depending on the solubility of the solute in water, andmany organic molecules and fluorchemicals have a density greater than1.5. Aqueous solutions of urea or guanidine, used for the dissociationof molecular complexes, generally have a specific gravity between 1.1and 1.17. Other important values are: Urine, about 1.03 or less, serum,about 1.06, red cells, about 1.09-1.15 Dynal magnetic particles, about1.3, fluorochemicals vary from around 1.5-2.0, including perflurooctylbromide, perflurohexane, various Fluorinert® 3M Materials. A RBC-magparticle complex, being less dense than the separating layer willusually range from about 1.1 to about 1.2 using Dynal particles of about3 micron average particle size. The following chemicals have thespecific gravities noted for them:

SPECIFIC CHEMICAL GRAVITY REFERENCE Perfluorohexane 1.682 F2 ChemicalsLtd.* Perfluoro-n-octane 1.75 F2 Chemicals Ltd. Perfluorodecalin 1.917F2 Chemicals Ltd. Perfluoromethyldecalin 1.972 F2 Chemicals Ltd.Perfluoroperhydrophenanthrene 2.03 F2 Chemicals Ltd FC-40 1.85 3MCompany** Perfluorotributylamine (FC-43) 1.9 3M Company FC-70 1.94 3MCompany FC-73 1.68 3M Company FC-77 1.78 3M Company 1,2 Dichloroethylene1.27 *London England **Minneapolis, Minnesota

Isotonic Ficoll® 400 solutions cover a density range up to 1.2 gm/ml andamino acids, sugars and proteins can be used to make aqueous solutionsof various specific gravities.

The density of various molecules and their solubility characteristicsare readily available in reference manuals such as the CRC PressHandbook of Chemistry and Physics (Chemical Rubber Co.).

Especially suitable in the invention are hydrophobic fluorochemicallayers, in between or adjacent to hydrophilic aqueous layers orsurfaces, with the specific gravity of each carefully chosen to increaseor decrease in the correct order, depending on the test. They shouldalso not irreversibly mix if shaken up by violent movement duringshipping and should settle back to separate and correctly layeredmaterials upon removal of the movement.

The materials should be inert to the components of the test, so as notto react with or alter cells or other mag-tagged materials as they passthrough. Fluorochemical liquids of relatively high specific gravity areuseful in creating a significant buoyant force to remove unboundmaterials from a surface. Other layers, for example organic solvents maybe selected for a desired reactivity. They can be very thin. One purposeis to improve separation of aqueous layers or surfaces.

Other methods used by the invention to maintain separation of layers arethe use of solid state baffles, meshes within the layers both withinterstices or pores large enough to freely allow migration of magneticparticle complexes but which would prevent convective or other currentflows that might cause intermixing of layers. Physical material, fixedor free, separating or retarding the mixing of adjacent layers such asfilters, baffles, or constrictions of the vessel can assist inmaintaining the zone stability.

Other methods involve treating the vessel, particularly the walls orselect wall sections to make use of surface tension effects relative tothe vessel wall and the liquid zones to prevent or control interminglingof layers.

As a statement of general applicability, in selecting the variousdensities for the assay construct of the present invention, the specificgravity of the uppermost layer just below the zone of sample additionshould be equal to or greater than the specific gravity of the sample,typically serum or urine or cell suspension, and the specific gravity ofthe soluble materials in the sample mixture. The top zone of sampleintroduction may contain reagents including mag-tagged reagents. Oncethe sample, first zone reactants and magnetic particles are mixed, thespecific gravity of the soluble materials may decrease slightly, assoluble sample materials such as proteins are further diluted in thesolute for the magnetic particle reagent and other reagents or diluents,helping to keep the layer with the sample in place on top of theadjacent zone.

When the zones are oriented in a top to bottom configuration, subsequentlower zones have a specific gravity higher than the next higher zone.Some zones may contain reaction products which will add to or modify thecomplex. Subsequent zones will purify complexes from non-reactedmaterials as the complex moves through the zones.

The invention envisages a whole new series of novel liquids employed innovel layers to obtain the necessary properties to exclude entry ofunwanted materials including non-miscibility, specific gravity, chemicalreactivity or inertness. Specialized zones, which may contain reactants,will be required by the various novel methods, procedures and processesnow made possible by the invention.

Forces—In the invention various forms of force may be used to movematerials of interest differentially through the zones of the continuousliquid medium, and onto surface capture zones. The preferred force ofthe invention is application of a magnetic field to move the magneticparticles, changing direction of or removing the magnetic field asnecessary, to separate magnetized reactants from non-magnetized entitiesand in or through layered zones appropriate to the test specific gravityand the intensity, direction and timing of the magnetic fields maychanged as suited to the steps of the procedure. Other forces usedselectively or combined in the invention include, for example,sedimentation, under gravity or by centrifugation, flotation,electrostatic charges, electrophoresis coordinated with selectedproperties of the liquid zones such as density or hydrophilicity toadmit passage of materials of interest and exclude MNOI.

The invention also envisages using mechanical forces physically movingreactive surfaces that have material bound to them down through denselayers so as to float off unbound materials and purify the boundreactants. And moving dense liquid layers up past fixed reactivesurfaces where reactants are bound to remove unbound reactants by shearor buoyant force.

Novel Reagents—Many research and commercial reagents are presentlyavailable containing antibodies or other ligands with magnetic particlesattached. These reagents are able to attach magnetic particles tomaterials of interest and are useful in methods where a magnet is usedto pull the complex to the vessel wall to separate it from othermaterials. Then materials not of interest are, aspirated, decanted orotherwise removed, and the remaining materials of interest can beresuspended and studied in isolation.

Dynabeads come with a variety of immunoreactants bound to them and comein various diameters and specific gravity. For example, some Dynabeadsare 2.8 microns in diameter with a specific gravity of 1.3 grams/cubiccentimeter.

Readable indicator labels such as enzymes, fluorophors, chemiluminescentmaterials, radioactive isotopes, and other labels may be attached tomaterials of interest in addition to magnetic particles and they may beread when delivered to a final reading zone on the magnetic complexes.These novel reagents apply to many assays, diagnostic tests, separativeprocedures and chemical syntheses.

Other novel reagents contemplated by the invention are mag-cellreagents, for example, reagent red blood cells of known blood typecomplexed with magnetic particles, to be used for blood bank diagnostictests.

Another reagent is a liquid dense enough to sink to the bottom of thevessel, for example, a fluorochemical, below the other zones which isadded at test reading time to float off MNOI not specifically bound tothe bottom surface antibody.

The invention also contemplates having reagents coated on a surface, forexample at the bottom of the vessel, which can react with and capturecomplexes forced against it.

Zones for Delivery of Materials of Interest . There is usually a need tomeasure the quantity of the isolated purified material that was presentin the original mixture sample. But often it may need to be collectedand removed for further operations upon it. Thus, the inventionenvisages various types of harvest zones to which highly selectedmaterials of interest from a starting mixture can be delivered, wherethey may be harvested and subjected to further downstream processing.

In one embodiment of the invention the bottom surface of the well istransparent so that materials delivered to this surface can be examinedmicroscopically in situ. And the bottom surface of the vessel can be aremovable; in the form of a glass slide for staining for microscopy. Or,when live cells are delivered for tissue culture, the bottom surface maybe a removable culture (Petri) dish.

In all, delivered cells may be studied by many varied downstreamprocedures including, for example, immunohistochemistry, confocalmicroscopy, PCR for molecular studies or RNA expression profiles.

When implementing ELISA immunoassays in the invention, chromogenic orfluorogenc substrates sited in the delivery zone may await the deliveryof enzyme linked analyte complexes to provide a signal that can bemeasured. Therefore, in assays, signal acquisition may be achieved byinstrument systems normally used in the art, in addition to visualobservation of accumulated cells in appropriate tests or scanning thetest construct or viewing the construct with a CCD video camera withappropriate pixel processing software. Instruments such as afluorescence microscope or reflection densitometer may measure specificsignals from labeled analyte complexes.

In one embodiment, mag-antibody tagged materials of interest aredelivered by magnetic field force through a liquid layer denser than thecomplexes themselves to a surface coated with antibody specific for theanalyte. There they attach by the sandwich principle. Some of thesedelivery destination areas may have specific capture mechanisms, such assurface attached antibodies or other ligands. to hold the material thereafter the magnetic field is removed.

Other embodiments of capture make use of study of material release afterthe magnetic field is removed to obtain information. When the magneticfield is turned off all materials not immunochemically bound by thesurface antibody will detach from the surface and float up into thedense liquid layer, if it is denser than the complexes themselves. Thisfreeing may be enhanced by agitation or swirling. One improvement tothis scheme is to print the antibody on the surface in a recognizabletwo dimensional pattern such as a cross or circle or alphanumericcharacter. Such a pattern will both represent a positive test result andact as its own control, minimizing signal noise and eliminating falsepositives due to non-specific contaminants.

Reading, signal processing. When the magnetic particles are coated withtyping antibodies or red cell capture antiglobulin reagent, the simplestand easiest way to measure the presence and quantity of red cells boundto the magnetic reagents either in flow or stopped on a magnet is adensitometer scan reading through a hemoglobin wavelength filter. Analternative is a CCD color camera with pixel assessing software. Incertain situations, chemical amplification of the hemoglobin signalusing a chromagen. e.g. tetramethyl benzidine (TMB) chromagen/substratesolution would be worthwhile. Enzyme amplification is another method ofuse. Often, visual observation is suitable for qualitative determination

Harvest Zone. The invention envisages, in some embodiments delivery ofMOI to a harvest area where highly purified proteins and other materialsmay be collected for further use, including for commercialmanufacturing.

In the case of separated cells, which can be delivered live and fullyfunctional in the invention, studies of highly selected living cells canbe done with confocal microscopy, laser scanning, FISH and othersophisticated procedures. Also, delivery of cells to microscopic slidesto other surfaces for counting, staining and microscopic examination,delivery to cell media for cell culture, or for molecular studies suchas PCR.

Various indicator labels such as enzymes and their substrates, reportermolecules like fluorophors, chemiluminescent materials, radioactiveisotopes, and other labels may be attached to the appropriate reagents,especially to non-magnetic tagged anti-human globulin, and analyteproteins in the manner well-known in the immunoassay art and thus serveto act as the element by which the progress and results of the test maybe observed and measured during the test run. In assays that utilize redblood cells, the hemoglobin in the cell can be used as the label forreading. In cases where a complex can react with a terminal surface, forexample be immunochemically bound to the surface, the magnetic particlecould be used as a label. The magnetic reagents can be prepared bymethods well-known in the art. Magnetic particles attached to proteinshave been made in the art and are well-known. Their process ofpreparation is well-known. When such labels are used in the method ofthe invention as a means to visualize the end point, suitable substratesor exciting media should be supplied at appropriate places in the assayconstruct.

Capture and Release Testing. The invention contemplates creating surfacecapture zones, by printing specific reagent antibodies on selected areasof the inside surface of the vessel. Inside surface areas coated withreagent antibody would selectively capture and bind MOI complexes forcedthere but not MNOI that might accompany them. Such inside surface areasalthough not liquid zones, may be considered zones that MOI can enterand be captured on and MNOI excluded or repelled from by variousmethods.

In one embodiment of the invention, a transparent bottom surface of thevessel becomes both a capture and test reading zone. It is coated withan antibody reactive with the MOI complex so that any magparticle-MOIcomplex forced by a magnetic field onto this bottom surface will becaptured and held there by the surface bound antibody.

The invention contemplates then removing the magnetic field and applyinga measured degree of a counter force able to eject complexes off thesurface. The degree of this force will be calibrated to remove nonspecific adhering MNOI but not break the antibody bond to MOI which willstay attached to be read. The purpose is to eliminate false positivetests due to signals from unwanted non specific MNOI that may persist onthe surface.

The preferred counter force of the invention is flotation force. This iscreated by adding or having present a resident bottom liquid layerdenser than the MOI complexes and any MNOI contaminants. The purpose ofthis dense layer is to create a relative buoyancy counterforce that willprovide flotation and float off any material not specifically bound tothe surface by surface antibody. Then the signal from the labeled MOIcomplex persisting on the transparent surface is read from outside thevessel.

Controlled gentle consistent release may be obtained by introduction ofa dense layer into the vessel at read time, which will sink to thebottom and float off any material not actively bound to the floor,leaving the bound material to provide a clean signal. The benefit ofadding this heavy liquid layer to the vessel after the MOI has beencaptured is that it may be made much denser than would be desirable in aresident bottom flotation layer that the mag-complexes would have to beforced through to the capture surface by a magnetic field. The additionof a liquid of greater specific gravity than the MOI complex at the endof the process allows for the use of centrifugal or gravitational forceto create contact with a reactive surface and still utilize buoyantforce to remove the unbound complex.

Another type of counter force contemplated by the invention to beapplied to test for specific binding of MOI after the magnetic field isremoved is, for example, electrostatic force. This can be created bycoating the surface with a negatively charged molecule such as heparinalongside the capture antibody which will repel negatively chargedproteins, and cells since all cells carry a negative charge on theirsurface. The invention includes modulating the charge of amphotericmaterials with buffers that adjust the pH of this zone so as to increasethe charge on molecules and so increase the electrostatic repulsionforce.

A third counter force that the invention may use is to reverse themagnetic field, to test for specific binding of mag-MOI complexes bysurface antibody. The reverse magnetic field force would be calibratedso as not to break the antibody bond holding MOI but still force off anynon antibody bound magnetic complexes that are present.

The invention contemplates any other suitable counter force to theantibody binding that may be applied to differentiate bound from nonbound materials at the surface.

Other embodiments of capture-release reading make use of the timing andrate of material release after the magnetic field is removed.

Although many current tests make use of surface bound antibody capture,none combines this with magnetic fields and a coordinated repellingbuoyant counter force to create exquisite test specificity andsensitivity.

Methods for release of magnetic particles from materials of interest.Some of these procedures, especially purification processes, requirerelease of magnetic particles before more processing is performed.Release of magnetic particles from materials they are bound to can beachieved in various ways by those skilled in the art before processingsteps are continued. This dissociation of material of interest from theparticles is particularly valuable as a step in the purification ofcells or molecules and can involve urea or guanidine solutions, pHchanges, enzymatic cleavage and other means.

Instrument and System Formats

Generic Schematic of a Device

Reference is made to the schematic representation appearing belowshowing a generic version of a device useful in the invention. Itrepresents liquid layers of different densities in a liquid columncontained in a vessel (not shown) such as a microtiter plate well. Inthe device, n, m and p are zero or an integer designating that suchzones may or may not be present. The device comprises preferably aplurality, i.e. at least two layers of different density, one of whichmay be the liquid sample. For some tests, only one layer need bepresent, In addition, there may be more zones than those indicated, andoverlapping of zones depending on the specific immunoassay beingperformed and the desired location of reagents. The bottom surface ofthe vessel in contact with the liquid column is also considered a zone.Each zone is contiguous with the adjacent zone and the device terminatesin a magnet which can be activated or deactivated at will. It may alsobe moved to various areas of the device.

Zone 1 Zone 2 Zone 3(n) Zone 4(m) Zone 5 (p) MAGNET

The materials of Zone 1 and those following have specific gravitiesdictated by the sequence of the steps of the particular assay, thereagents and sample. In general, proceeding from the uppermost to thelowermost layers, they will increase in specific gravity and otherwisebe so designed that the lower specific gravities of unbound reactants inthe assay system remain in the lower density layers while the reactedreagents settle or are forced into the higher density layers andultimately against the vessel wall at the bottom of the liquid column.The separation of these zones of different density can be enhanced byselecting materials that are poorly miscible with each other e.g., oil,fluorochemical liquids, or oil-like materials and water wherein the oilmay be of higher or lower density than the water. The vessel wall,typically at the bottom of the liquid column, can contain reactivematerial such as an immobilized antibody or antigen. The concept of theinvention is aided by the use of the magnet which attracts the reactedmagnetic complex yielding a much faster settling of the reacted taggedreagents to the magnet area than would occur by simple gravity andelapsed time. The specific gravity of the complex containing the MOI canbe less dense than the liquid zone above the vessel wall reactive zone,thus allowing the use of buoyant force to remove unbound material fromthe surface by floatation.

Role for the Invention in Automated IVD Instruments

The preferred embodiment of the invention for use in an automatedtesting instrument is to make use of microtiter plates and the automatedliquid handling and robotic systems that are widely available to servethem. Microtiter plates and pipetting, mixing and reading systems arecommon laboratory tools. When Dynal Mag particles (around 2.8 microns)are used in microtiter plates, immunoassays or blood bank procedures,0.1×10⁶ to 1.0×10⁷ Mag particles per well are sufficient.

It is possible to perform a large number of diagnostic tests such assandwich immunoassays or indirect anti-globulin blood bank tests.Following the procedures as described for single vessels, the automatedinstrument of the invention employs kits comprising microplates withwells prefilled with mag-particles and labeled reagent antibody, adenser liquid separation layer, and capture antibody printed on thebottom surface as described. To perform tests, unknown samples arepipetted into wells by the robot systems, a magnetic field applied andreleased, and the captured MOI label read from below.

Because of the large number and great variety of combinations andpermutations of reactants and reaction schemes possible, the device ispresented in connection with particular reference to the proceduralaspects of the device. Those skilled in the art will easily be able toadapt the construct to a specific assay and configuration.

Array of Bottomless Vessels Format

One instrument format for use in chemical synthesis processer of theinvention, is an array of bottomless vessels placed into a bathcontaining a layer of an inert dense liquid, for example afluorochemical, such that there is a continuous liquid connectionbetween all the vessels through the fluorochemical layer in the bath.The upper surface of the fluorochemical layer is now the functionalbottom of each well for all suspended materials except mag-complexesthat can be forced into the bottom layer by magnetic field force. Byapplying a magnetic field, magnetic reactant complexes are forced downinto this layer leaving behind any other unwanted reactants in theliquids of the vessel. Highly purified complexes are then movedlaterally by relocating the magnetic force, then allowed to float upinto an adjacent bottomless vessel where the reactants for the nextstage of the process await them. In this manner, a long series ofchemical synthesis steps can be performed on the magnetic particlecomplex with absolutely no carry over of reactants from previous steps.The advantage of this instrument format is there are no moving parts, novolumes of washing solutions and no liquid handling pumps and no toxicwaste sinks.

Examples of Applications

IVD Tests

Immunoassay Applications

General Method for Immunoassays: Provide a first reactant or bindingpartner, typically an antibody to an analyte to be detected (such as hCGor HBsAg), attached to a movable surface, for example a magneticparticle if magnetic forces will be used, or a plastic surface, such asa flat surface if manual movement of the object is to be used.

-   -   1—Mix the first reactant for an appropriate time with a sample        suspected of containing the analyte that can react with the        first reactant and a labeled reagent capable of reacting with        the reacted analyte or competing with the reacted analyte for        combination with the first reactant.    -   2—Separate the first reactant from the unbound label by applying        a force that will move the complex through a solution that will        create a separate cleaning zone. This solution ideally will stay        separate from the original mixture and could be more dense or        less dense than the original mixture and may be immiscible with        that mixture such as oil and water.    -   3—Move the complex to a reading zone which can directly detect        the label or where the label can further react with a substrate        to create a material that will be detected in the reading zone.

In some immunoassays especially to assay for a state of immunity (forexample immunity to Rubella) which involve a labeled antiglobulinreagent it is desirable to separate the sample and first reactantcomplex from unreacted sample prior to exposing the complex to a labeledantiglobulin reagent. This is accomplished by adding a 1st separationstep prior to the addition of the labeled antiglobulin reagent.

In fact, the second variation described above can be further simplifiedfor a home pregnancy test by utilizing a very low specific gravitymagnetic particle (for example less than 1.0) in conjunction with theurine sample (1.0 to 1.03). This simplification will bring the magneticparticles through the urine sample and into contact with the reactivesurface by applying a magnetic force, and removing the unbound particlesbecause of their buoyancy and by agitation, such as discarding the urinefrom the container after the magnetic force is removed. The reactionzone is observed for bound magnetic particles.

Immunoassay Antibody Detection Method

The method also applies to the detection of antibody to disease relatedantigen in a sample such as the ToRCH assays—Toxoplasma, Rubella, CMV,HSV—which are often performed in a sub-population of women ofchild-bearing age and infectious diseases assays of interest in bloodbanking such as Hepatitis C (HCV), HIV and CMV which are used to excludeblood for transfusion. In these assays, the disease related antigen isbound to the magnetic particles (for example 0.3 micron and specificgravity 1.3). An antibody reactive with human immunoglobulins is boundto the reactive surface at the bottom of the vessel (microtiter platewell) and overlayed with a dense separating zone (specific gravitygreater than the magnetic particles, their suspending solution and thesample). Patient's sample (typically serum, specific gravity less than1.1) is added to the vessel, mixing with the magnetic particles, andantibody if present in the sample reacts with the antigen on themagnetic particles. The magnetic particle sample mixture is separatedfrom the reactive surface at the vessel bottom by the separating zoneuntil a magnetic force is applied moving only the magnetic particles andany bound immunoglobulin through the separating zone and into contactwith the antiglobulin reagent bound to the bottom surface, all unboundsample material remains floating in the first sample zone. After themagnetic particles are brought into contact with the antiglobulinreactive surface the magnetic force is removed and the unbound magneticparticles float off the surface, leaving only magnetic particles withbound antibody (MOI) bound to the surface. The reaction surface isobserved for the presence of bound magnetic particles which indicate thepresence of antibody to the disease agent in the patient's sample.

Blood Banking

One area in which the invention is particularly suited, is the field ofimmunohematology, i.e., the set of blood bank laboratory tests that arenecessary before blood transfusions can be prepared and administeredsafely to patients. Briefly, all blood bank serological tests are basedupon detecting whether a red cell antibody binds to antigens on redcells of patients or blood donors. The novel magnetic particle methodsof the invention can be applied to all of the standard tests of theblood bank laboratory, including immunoassays routinely performed fortransfusion transmitted diseases such as HIV and Hepatitis. Theinvention offers significant advantages in the performance of variousesoteric and research immunohematological tests.

The invention contemplates three general test methods in blood banking.Other variants of these protocols are not excluded.

First method: Direct Red Cell Phenotyping

This method employs reagents consisting of magnetic particles directlytagged with specific known antibodies. These reagents are incubated withand attach to red cells that carry the cognate antigen on their surfacebut do not attach to red cells that lack the antigen.

As described in Example 6 above, magnetic particles tagged with aspecific antibody (for example Anti-A) are mixed with red cells whichmay or may not contain the A antigen. The magnetic particle taggedantibody complexes with the A antigen on group A red cells and will pullthose red cells under the influence of a magnetic field to the magnetthrough more dense liquids. Group O or group B red cells which both lackA antigen will not move under that influence.

Thus, unknown red blood cell antigens may be determined by selectingspecific reagent antibodies such as Anti-A, Anti-B, Anti-D and the like,in place of the serum used in crossmatch test above. Similarly, unknownantibodies in serum can be determined using specific reagent red bloodcells in the method. Other specific determinations can be made as wellbe seen below.

The test is read as positive if red cells are observed on the bottomsurface of the vessel next to the magnet. In a negative test no redcells are observed on the bottom surface.

The advantage of this method over previous magnetic cell separationmethods of having a dense zone is that in a negative test the cells arewell separated from the reading zone. In previous methods they areclosely adjacent. Thus, a negative test is more clearly differentiatedfrom a positive test. Moreover, no decanting is necessary.

Second Method: Capture and Release by Surface Bound AHG

In this method, red cells of known or unknown blood group, tagged withmagnetic particles as described above, are incubated with unknown orknown red cell antibodies, respectively.

The magnetic particle tagged red blood cells are pre-prepared anddispensed into the reaction vessel by a single pipetting step. Themagnet tagged red cells are then reacted with a reagent or patientsample that may or may not have antibody to the red cell antigens. Aftersufficient time for the reaction to occur, the magnet tagged cells aremoved by the application of a magnetic field through a dense separatingsolution and to a reactive surface coated with a bound antiglobulinreagent. The magnetic field is removed and bound red cells stay attachedto the reactive surface. Unbound red cells float off the surface andinto the more dense separating liquid. In a positive test, red cells areobserved remaining bound to the capture surface. In a negative test, nored cells are observed remaining on the capture surface.

More specifically, a mixture of donor's red blood cells, patient serumand magnetic particle with a red cell binding partner attached to it(lectin, anti-human red blood cell antibody, or red cell bindingchemicals) is prepared and either preincubated or allowed to incubate inthe liquid medium.

During the incubation:

-   -   1. The magnetic lectin complex will react with any red blood        cells since the lectin chosen is a universal red blood cell        reactant.    -   2. Any antibody present will react with just those red blood        cells carrying the specific red blood cell antigens, resulting        in red blood cells coated with antibody. If some red blood cells        become coated with antibody, the AHG test is positive. In no red        blood cells become so coated, the test is negative.    -   3. A magnetic field is applied to the reacted mixture pulling        all magnet tagged red blood cells, coated or non-coated, through        a dense liquid zone (selected to have a specific gravity greater        than the magnetic particles red cell complex) where they are        washed free of all proteins except those specifically bound to        red cell surface antigens, and on to a reaction zone with        immobilized antiglobulin reagent.    -   4. After the red cell magnetic particle complex has been        contacted to the antiglobulin reagent surface the magnetic field        is removed and unbound red cell complex (specific gravity        typically less than 1.2) is removed from the surface by        floatation in the separating liquid of higher specific gravity.        The unbound cell complex is less dense than the separating        liquid and floats off the surface. The reaction surface is        observed for bound red cell complex, indicating the presence of        an antibody attached to the red cells.        Third Method: Passage Through Labeled AHG Zone

In this method red cells are tagged with mag-particles and incubatedwith antibody exactly as in the second method just above. Coated redcells are washed in the same manner. However, detection of the antibodycoat is done by moving the cells through a denser liquid zone containingfree labeled AHG where coated cells pick up label and non-coated redcells do not. In a positive, test label is observed in the end readingzone. In a negative test, no label is observed in the end reading zone.

Separation of unreacted AHG from the magnetic complex is achieved bydrawing the complex through liquid zones of increasing density, so thatlighter unreacted labeled AHG will remain in its original lower densityregions and will not take part in the reading determination. The effectof the magnetic pull-through is enhanced by providing layers ofincreasing density gradient as the flow goes through the various zones.By this means, debris and unreacted material will remain in areasappropriate to their densities whereas the heavier complexed materialswill be drawn through to the layers of higher density. It should beapparent that the foregoing reaction scheme does not depend uponseparation of bound magnetic particles from unbound magnetic particles,but rather on the separation of the bound labeled AHG from unboundlabeled AHG.

More specifically

-   -   1—attaching a magnetic red cell binding partner, such as a        lectin or antibody, to a red cell to facilitate the movement of        the cell through repugnant denser zones by a magnetic field, can        be done simultaneously with the first incubation step of the        assay, the interaction of red cells and serum from different        sources. Incubate the reactants of the test with the sample,        such as RBCs, antibody, and a magnetically tagged universal red        blood cells reactant, such as a lectin, i.e., Mag-lectin as        described above, in Zone 1. Allow the reaction, if any, to take        place.    -   2—apply the magnetic field to pull the RBC-antibody-lectin-Mag        complex through Zone 2, or Zone 3 if present, and be washed        therein and then through a Zone of labeled AHG, for example,        enzyme labeled AHG, in a higher density Zone 3 or Zone 4. There        the AHG portion of the enzyme labeled AHG complex reacts with        the antibody portion of the complex. Unreacted AHG stays in its        own density zone.    -   3—separating the magnet tagged red cells—with bound label from        the unbound label by moving the red cells through a denser zone        which is poorly miscible with the labeled antiglobulin reagent        zone.    -   4—observing the label directly, or indirectly by moving the        enzyme linked particles into a substrate containing zone where        an amplified signal can be obtained.        Further Discussion

All of the standard and many esoteric and research immunological testscan be performed by the second method. This includes forward and reverseABO typing, red cell phenotyping , red cell antibody screening andidentification, crossmatching including multiple donor crossmatching,detection of minor red cell populations and fetal maternal hemorrhagestudies.

ABO forward typing of patients and donors and Rh typing may be performedreadily by the first method using mag-tagged anti-A and anti-B reagents.Reverse typing may be performed by the Second or Third method usingnovel reagents, pre-mag-tagged known A1 and B cells, and patient ordonor serum. Antibody screening and antibody identification may beperformed by the Second or Third method using novel reagents, mag-taggedknown O cells, and patient or donor serum. Antiglobulin crossmatches maybe performed by the Second or Third method by tagging donor cells withmag-particles and incubating with patient serum.

One particular example of the First Method is given to illustrate onepractical example of use of the invention in a blood bank laboratorytest to detect and quantitate fetal red cells in blood samples fromRh-negative mothers. FMH testing is very important in the field ofperinatal medicine but present methods are inadequate. This procedure isdone for every Rh negative mother who has delivered an Rh positive baby.The magnetic method can be easily adapted to perform this test. In thisexample of the Direct Mag-Particle Test, magnetic particles coated withanti-D (Rh) react with any Rh positive fetal cells in the Rh negativemother's blood sample and with the application of a magnet separate thefetal cells from the mother's cells. In the preferred embodiment of theFMH procedure, the magnetic particle test kit procedure would be asfollows:

A maternal red cell suspension is introduced into a vessel containing atop layer of anti-D magnetic particles solution in a layer less densethan the layer below. Anti D Mag-particles will bind to Rh Positivefetal red cells but not to any Rh Negative maternal red cell. After thered cells react with the magnetic particles, a magnetic force field isapplied to pull the Rh positive fetal red cells attached to magneticparticles down the through the denser zone and to the bottom readingzone where these magnetic bound cells can be quantitated. In onepreferred embodiment, the magnetic field is applied at the underside ofa microplate in which the test solution is added to the mother's redblood cell suspension. The degree of magnetic force applied to themembrane may be selectively adjusted to vary the width or surface areaof the capture line or zone.

The fetal cells are quantitated by measuring the density of red cellsstopped in the capture reading zone of the column. Read OD in capturezone using a colorimeter.

The key reagent is a suspension of magnetic particles (iron) that arecoated with anti-D antibodies. These may be prepared by techniqueswell-known in the art. The concentration of the magnetic particles andmother's blood used in the assay will be important and needs to bestandardized, but in general there should be an excess of magneticparticles to the expected maximum fetal cells in the assay.

Testing Donors for Transfusion Transmitted Diseases.

Tests for antibody in human serum reactive with infectious diseaseagents such as HIV, HCV, CMV. These methods utilize the same separatingsolution and antiglobulin coated reaction surface in vessels, such asmicrotiter plate wells, as the General Blood Bank Assay, but differ inthe utilization of an antigen coated magnetic particle in place of a redcell capture magnetic particle. The immunoassay antibody detectionmethod for infectious diseases can be done in parallel with the otherblood bank assays utilizing the same general format and timing sequence.

The practical advantage to the blood bank of methods using the inventionis that all of the immunohematologial and infectious disease testsrequired for pretransfusion testing of blood donors can be done in thesame microplate, on the same automated instrument at the same time. Thiswould lead to great simplification of logistics of patient and donorspecimen handling and aliquoting for the laboratory.

For detection of specific antibodies in patient's serum, such asA-antigens, B-antigens, or O cells and Anti-A, Anti-B, and Anti-AB, thetest is run in the same way antibody screening is performed. In eithercase, the reactants in the form of the magnetically tagged reagent cellsor reagent antibodies are added directly onto Zone 1 and allowed toreact therein and then pass into other Zones of higher density.Immobilized AHG or labeled anti-human globulin (enzyme label, forexample) present in a lower zone is used to either immobilize or labelany reacted complex for detection.

Mag Crossmatch

The reaction sequence for a positive crossmatch using a labeled AHGreagent can be described as follows:

-   1. antigens (−donor red blood cells)+antibodies (recipient    serum)+Mag-lectin→Maglectin.antigens.antibodies-   2. apply magnetic field to move complex to the AHG.enzyme    zone→Mag-lectin antigens.antibodies+AHG-enzyme→a)    Mag-lectin.antigens.antibodies.AHG.enzyme (if negative—no reaction    here)-   b) Mag-lectin.antigen.antibody.AHG.enzyme on magnet move to enzyme    substrate zone for color development showing positive. No color    indicates negative.

The foregoing is illustrative of a crossmatch blood bank test, but alsodescribes any blood bank serology method by substituting either antiserafor patient serum or reagent red blood cells such as screening orreverse grouping cells for the donors in a liquid phase system, TheMag-lectin reagent enables a method for performing all blood serologytests with the labeled or immobilized antiglobulin reagent, and usingonly regular non-magnetic reagents in addition (for example antiserasuch as anti-A or anti-D). This eliminates the need to develop a wholeseries of magnetic reagents of different specificities in the preferredembodiment.

The reading of the labeled AHG is facilitated by providing a suitablesubstrate for the label at the reading zone of the assay construct. Tocreate the labeled antihuman globulin (AHG) reagent, rabbit anti-humangamma globulin is bound to a detection label such as an enzyme, (e.g.horseradish peroxidase, Beta-galactosidase, etc.) a fluorophor,chemiluminescent material, radioactive isotope or the like, as iswell-known to one skilled in the art.

It should be noted that the foregoing reactions apply to thedetermination of any blood constituent by the appropriate selection ofreagents and magnetic and tagged particles.

The present invention enables the separation of bound Mag particles fromunbound Mag particles, if desired, through the judicious selection ofthe specific gravity of the intervening layers.

Microscopy. This principle of removing unreacted cells or debris fromthose tagged with magnets can also be applied to microscopy. Inmicroscopy, it is desirable to decrease the amount of debris from theviewing field. Since the debris is typically composed of cellularmaterial and fibers or dust, these materials can be removed by flotationby pulling the magnet tagged cells through a solution with a specificgravity that exceeds that of the cells and debris alone, and deliveringthem to the surface of a microscope slide for staining and microscopicexamination in a clean field. The floating debris may be rinsed awaybefore microscopic viewing or it may be rendered invisible by being in aseparate depth of field above the separation layer. For example, a thinlayer of dense fluorochemical on the slide will prevent debriscontacting the slide and allow for the removal of the debris floating ontop of the fluorochemical layer while the selected material attached tothe magnets is held on the slide.

Cell Separations. The invention, when used for separation of cell types,also provides for novel, magnetic-particle tagged or capture antibodyreagents which react with cell surface antigens the blood group antigensof red blood cells important in transfusion medicine, the CD antigens ofT cells and the cancer antigens of malignant cells, for example. Thesereagents comprise, for example, the usual blood typing reagents ofvarious specificities as used in blood bank laboratories but modified inaccordance with the present invention. That is, they are tagged withmagnetic particles or beads, so that red cells (or any other bloodcells, such as white cells and platelets) coated with the magneticcapture reagents and sample antibody coated onto tagged reagent redcells can be moved as a complex in a magnetic field. In addition, novelmagnetic tagged reagents comprising entities such as lectins,non-immunological binding pairs and universal binding agents which willbind to all blood cells, regardless of blood type, may also be used inthe invention.

Such blood cells coated with these reagents can in some embodiments becaptured by the magnetic field of the invention and held stationaryrather than being moved, for reading or for further processing in thetest such as washing, concentration, prolonging and enhancing antibodyincubation and the like. For example, the magnetic field can hold theparticles in place and the liquid zones moved past the stationaryparticles. If the magnetic field is removed, the cells will continue toflow with the liquid according to the individual test protocol.

The magnetic particle tagged reagents enable phenotyping of a vast rangeof cells for a vast range of phenotypes. Cells to which these magneticreagents bind can be delivered by the magnetic field of the invention toa detector zone can indicate the presence of the specific antigens onthe cell surface corresponding to the specific antibody of the taggedparticle complex. Selected cells can be delivered to a harvest areawhere they can be subjected to further downstream processing such ascell culture or PCR.

There are many procedures that employ separation or segregation of cellpopulations of interest such as:

Sentinel Lymph Node Biopsy Application

In sentinel lymph node biopsy, a sample of lymph node is disaggregatedinto a small suspension volume. This is introduced into a well withthree layer zones. The top zone contains magnetic particle taggedanti-epithelial cell antibody binds only to breast cancer cells. Thelower separating liquid zone is an inert fluorochemical liquid of higherdensity or other dense liquid which separates the top layer from theculture layer zone which is made up of a living cell sustaining solutionof even higher density than the separating layer. Alternatively, theculture zone can be of similar density as the sample but is separatedfrom the sample zone by a baffle on the sides and the dense separatingzone on the bottom. A magnet is applied to the bottom of the well whichmoves the magnetic particle tagged cancer cells selectively to thetransparent bottom surface leaving all of the other lymph node cellsfloating in the top layer as they are unable to enter the denserseparating layer. There they can be examined microscopically by apathologist. Either the bottom layer or the top layer may also containseveral varicolored immunohistochemical stains that bind to the cancercells, allowing multiplex phenotyping of the cancer cells for her orother phenotypes. Following examination they are also available for cellculture by moving them to the culture zone or PCR molecular testing bymoving them to an appropriate zone.

CD4 T Cell Levels in HIV Patients

Another embodiment of the invention concerns a simple measure of CD4 Tcell levels in HIV patients suitable for use in the field. A measuredblood or buffy coat sample from the patient is introduced into the topzone layer of a column which contains labeled-buoyant-mag-anti-CD4antibody reagent. After time for specific reaction of antibody reagentwith all and only CD4 T cells, a magnetic field is applied forcing justthe mag-tagged CD4 T cells down through a denser layer which will rejectall other T cells (and all other cells of any kind) to the transparentbottom surface of the vessel containing the continuous liquid column.The CD4 T cell count may be obtained by counting the CD4 T cellsdelivered to the bottom surface microscopically or measuring their labelquantitatively with a densitometer.

CD4+/CD25+ T Reg Cells

This subset of T cells, CD4+/CD25+ T Reg Cells, has become veryimportant in immunological research, in cancer therapy, diabetes, inautoimmune diseases and in organ transplantation. T Reg cells areessential for immunological tolerance to self. In cancer, they have beenshown to infiltrate the tumor and block the body's natural anti-tumorimmunity. It has been possible to cure Diabetes Type 1 in mice andefforts in human diabetes are being actively pursued showing theimportance of these cells. ‘Educating’ the immune system to accepttransplanted grafts as self is a formidable challenge that immunologistshave been tackling for decades. Efforts are being made to manipulate Treg cell populations to allow transplantation without immunosuppresion.There is a need for better methods of detecting, isolating and countingthese cells in many clinical situations. The invention envisages threemethods of performing this assay which illustrate the great flexibilityof the general method in providing opportunities for creating variationsthat achieve special purposes. First, using the method above to isolateCD4+ T cells, but incubating the buffy coat cells with binding mag.CD4antibody and fluroescin labeled Cd-25 antibody. All CD4+ T cells will beforced to the bottom surface with the CD25+ subset identified for studyby its flouorescin label. Second, using the same method to force allCD4+ cells to a bottom surface which in this case has attached anti-CD25antibody. When the magnet is removed, flotation will remove all CD4+cells not bound to the surface by the fixed anti-CD25 antibody leaving apure subset of fluorescin CD4+ CD25+ T cells at the surface for study.Third, by incubating buffy coat cells with both mag-CD4 antibody taggedwith small mag particles, and CD25 antibody tagged with larger magparticles, and providing two fluid separating zones, a less dense layeron top of a more dense layer. In this case, magnetic field strength issuch as to force the CD4+ tagged T cells down into the first zone butnot intense enough to force them into the denser zone. CD4+ CD25+ Tcellstagged with both mag-antibodies will be forced all the way to the bottomsurface.

Molecule Separations

Molecule separations. It is sometimes desirable to purify materials byspecifically binding material to a capture molecule, for example anantibody bound to a magnetic particle, and then removing the boundmaterial from unbound material and finally releasing the bound material,regenerating the capture molecule. This can be done with a magneticparticle coupled to an antibody specific for a material to be purified.Consider a baffled container with a separating zone covering the bottomand part way up into each separate baffled zone, one of which containsmaterial to be purified and the other of which contains a releasingchemical, for example, an acidic or basic or high salt solution. Mix themagnetic particles with the material to be purified and then force theparticles through the separating zone and into the release zone. Mix inthe release zone and then force the magnetic particles back through theseparating zone and into the zone containing the material to bepurified, mix and repeat this cycle as needed. At the end the purifiedmaterial will be concentrated in the release zone and available forfurther processing.

Chemical Syntheses

As described in Example 8 above, the invention is directly applicable tochemical processes where it is necessary or desirable to provideseparation steps between addition steps so that no materials involved inthe previous step contaminate the next reaction.

In chemical synthesis the procedure involves:

-   -   1—providing a movable magnetic particle on which chemical        synthesis can occur    -   2—in a plurality of separate chemical addition zones for        different aspects of processing, (for example a bottomless        microtiter plate placed into a layer of an inert solution or        liquid, for example a fluorochemical, such that the bottom of        each well is the fluorochemical) connecting with each other        through the fluorochemical, move the particle by magnetic field        from one zone to the next zone, through an inert layer selected        (as a separate separating zone that will not mix or react with        material in other zones or on the particle. The separate        chemical zones can contain acids, bases, organic solvents, amino        acids or other chemicals that are appropriate for the synthesis.        The inert solution, for example a fluorochemical, is selected to        be non-reactive with any reactants and preferably poorly        miscible with the reactants, a liquid at the temperatures used        in the process, typical examples could include        perfluoro-n-octane, perflurodecalin, and perflurohexane among        others. In a similar sense a less dense organic solvent could be        selected that would float on top and be used as a cleaning zone.    -   3—The movement of the particle up, down or over through the        addition and removal steps is done in the sequence needed to        synthesize the desired material on the particle. There can be        multiple types of cleaning zones in the same process, for        example multiple reactant zones with a specific gravity between        1.0 and 1.4 and a more dense cleaning zone underneath consisting        of a dense fluorocarbon (density 1.5 to 2.0) and a less dense        organic solvent, for example acetone, floating on top of the        multiple reactant zones.

What is claimed:
 1. A method for detecting the presence or absence of an antigen on a blood cell in a liquid medium containing interfering proteins which comprises:
 1. providing in a vessel: a) a continuous liquid medium comprising relative to a vertical plane at least two separate liquid zones of different densities, a first zone of which comprises a reaction incubation zone and comprises a first liquid and a second zone of which comprises a second liquid each of said first liquid and said second liquid being contiguous with the other, and an end reading zone present in said liquid medium at a point which permits performing Step 5 below, b) a blood cell sample suspected of having said antigen to be determined, c) an antibody specific for the antigen sought to be determined, and d) magnetic particle tagged moieties which are reactable with said blood cells, to form a movable complex therewith, the components b), c) and d), being present in said first zone, e) a free anti-human immune globulin (AHG), with an attached readable label, present in said second liquid zone, having a density greater than the density of the first zone said AHG being capable of reacting with c) above, wherein said liquid in said second zone has a buoyant effect on, and is repugnant to, the presence of interfering proteins, unreacted said magnetic particle tagged moieties and said blood cells, if any,
 2. allowing a complex of b) and d) to form in a negative test and a complex of b), c) and d) to form in a positive test, all in said first liquid zone,
 3. applying a magnetic field to the complexes formed in Step 2 to move them into the second, denser, liquid zone into contact with said AHG present therein, wherein said AHG attaches to the antibody c) of said complex b), c) and d) if said antibody is present, thereby forming a further AHG complex with b), c) and d) and thereafter moving the further AHG complex to the end reading zone,
 4. removing the magnetic field from the further complex, whereby any b), d) complex that may have formed and any unreacted magnetic particles not bound to the AHG, are dislodged from said further AHG complex due to the repugnant nature and buoyant effect of said second zone liquid on said unreacted unbound magnetic particles,
 5. observing the complexes in the reading zone for the presence or absence of the AHG attached label, a positive test for said antigen sought to be determined being indicated by the presence of the AHG label thereon.
 2. The method according to claim 1 wherein the AHG is labeled with a readable enzyme.
 3. The method according to claim 1 wherein the cell sample is human cells and the antigen sought is a human antigen.
 4. The method according to claim 1 wherein the moiety in Step 1d) is a lectin.
 5. The method according to claim 1 wherein the specific antibody employed in Step 1c) is Anti-A, Anti-B or Anti-D antibodies and the specific antigen sought is Group A, Group B or Group D, respectively.
 6. The method according to claim 1 wherein the density of the second liquid is higher than the density of the complex lacking the antigen sought for in Step 1c).
 7. The method according to claim 1 wherein the cell sample of Step 1b) is a donor's red blood cells, the antibody of Step 1c) is a patient's serum and the method is a crossmatch method.
 8. The method according to claim 1 wherein the lower-most liquid is a perfluorochemical.
 9. A method for detecting the presence or absence of an antibody in a blood cell in a liquid medium containing interfering proteins which comprises:
 1. providing in a vessel, a mixture of: a) a continuous liquid medium comprising relative to a vertical plane at least two separate liquid zones of different densities, a first zone of which comprises a reaction incubation zone and comprises a first liquid and a second zone of which comprises a second liquid each of said first liquid and said second liquid being contiguous with the other, and an end reading zone present in said liquid medium at a point which permits performing Step 5 below, b) blood cells having cell antigens thereon, and c) a sample suspected of comprising antibodies to said cell antigens, and d) magnetic particle tagged moieties which are reactable with said blood cells, to form a movable complex therewith, the components b), c) and d) being present in said first zone, e) a free anti-human immune globulin (AHG), with an attached readable label, present in said second liquid zone having a density greater than the density of the first zone, said AHG being capable of reacting with c) above if antibodies are present in said sample, wherein said liquid in said second zone has a buoyant effect on, and is repugnant to, the presence of interfering proteins, unreacted said magnetic particle tagged moieties, and unreacted blood cells,
 2. allowing a complex of b) and d) to form in a negative test and a complex of b), c) and d) to form in a positive test, all in said first liquid zone,
 3. applying a magnetic field to the complexes formed in Step 2 to move them into the second, denser, liquid zone into contact with said AHG present therein, wherein said AHG attaches to the antibody c) of said complex b), c) and d) if said antibody is present, thereby forming a further AHG complex with b), c) and d), and thereafter moving the further AHG complex to the end reading zone,
 4. removing the magnetic field from the further complex, whereby any b), d) complex that may have formed and any unreacted magnetic particles not bound to the AHG, are dislodged from said further AHG complex due to the repugnant nature and buoyant effect of said second zone liquid on said unreacted unbound magnetic particles,
 5. observing the complexes in the end reading zone for the presence or absence of the AHG attached label, a positive test for said antigen sought to be determined being indicated by the presence of the AHG label thereon.
 10. The method according to claim 9 wherein the blood cells in Step 1b) and in Step 1c) are of human origin, and the blood cells in Step 1b) are red blood cells.
 11. The method according to claim 9 wherein the moiety in Step 1d) is a lectin.
 12. The method according to claim 9 wherein the specific cells employed are group A, group B and group RhD respectively and the specific antibodies sought in Step 1c) are Anti-A, Anti-B or Anti-D antibodies.
 13. The method according to claim 9 wherein the specific cells employed are group O red cells phenotyped for multiple red cell antigens and suitable for use in antibody screening and antibody identification, and the specific antibodies sought in Step 1c) are unexpected red cell antibodies.
 14. The method according to claim 9 wherein the density of the second liquid is higher than the density of the complex lacking the antibody sought for in Step 1c).
 15. The method according to claim 9 wherein the cell sample of Step 1b) is a donor's red blood cells, the antibody of Step 1c) is a patient's serum and the method is a crossmatch method.
 16. The method according to claim 9 wherein the lowermost liquid is a perfluorochemical.
 17. A method for detecting the presence or absence of an antibody in a liquid medium which contains interfering proteins which comprises:
 1. providing in a vessel, a mixture of : a) a continuous liquid medium comprising at least two separate liquid zones, a first zone of which constitutes a reaction incubation zone and comprises a first liquid and a second zone of which comprises a second liquid, each of first liquid and said second liquid being contiguous with the other, and an end reading zone present in said liquid medium at a point which permits performing Step 5 below, b) in said first zone, a sample suspected of containing said antibody to be determined, and magnetic particle tagged moieties comprising an antigen specific for the antibody sought to be determined capable of forming a first complex therewith if said antibody is present, c) a free anti-human immune globulin (AHG), with an attached readable label, present in said second liquid zone, having a density greater than the density of the first zon; said AHG being capable of reacting with antibody b), above, wherein said liquid in said second zone has a buoyant effect on, and is repugnant to, the presence of interfering proteins, unreacted said magnetic particle tagged moieties and blood cells present in said first zone, if any.
 2. allowing said sample and said magnetic particle tagged moieties in b) above to form a reaction mixture comprising said first complex in said first zone, if said antibody is present, and unreacted magnetic particles, if any, in said first zone,
 3. applying a magnetic field to the complexes formed in Step 2 to move them into the second, denser, liquid zone into contact with said AHG present therein, wherein said AHG attaches to the antibody of said first complex, if said antibody is present, thereby forming a further AHG complex with b), and thereafter moving the further AHG complex to the end reading zone,
 4. removing the magnetic field from the further complex whereby any unreacted magnetic particles not bound to the AHG are dislodged from said AHG present in said second liquid zone due to the repugnant nature and buoyant effect of said second zone liquid on said unreacted unbound magnetic particles.
 5. observing the complexes in the end reading zone for the presence or absence of the AHG attached label, a positive test for said antigen sought to be determined being indicated by the presence of the AHG label thereon.
 18. The method according to claim 17 wherein the antibody sought is a member of the group consisting of antibody to toxoplasma, rubella, cytomegalovirus, herpes, hepatitis and HW.
 19. The method according to claim 17 wherein the sample of Step 1b) is of human origin.
 20. The method according to claim 17 wherein the second liquid zone has a density higher than unreacted reagent of Step 1c), and the lowermost liquid is a perfluorochemical. 